BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37088616)

  • 1. De Novo Malignancy After Adult-to-Adult Living Donor Liver Transplantation: A Single-Center Long-Term Experience.
    Masuda Y; Mita A; Ohno Y; Kubota K; Notake T; Shimizu A; Soejima Y
    Transplant Proc; 2023 May; 55(4):952-955. PubMed ID: 37088616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretransplant Hepatic Malignancy Increases Risk of De Novo Malignancy after Liver Transplantation.
    Park GC; Hwang S; Ahn CS; Kim KH; Moon DB; Ha TY; Song GW; Jung DH; Yoon YI; Cho HD; Kwon JH; Chung YK; Kang SH; Choi JU; Jung IJ; Lee SG
    J Korean Med Sci; 2020 Mar; 35(11):e69. PubMed ID: 32193900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De Novo Malignancy Following Adult-to-Adult Living Donor Liver Transplantation Focusing on Posttransplantation Lymphoproliferative Disorder.
    Mizuno S; Hayasaki A; Ito T; Fujii T; Iizawa Y; Kato H; Murata Y; Tanemura A; Kuriyama N; Azumi Y; Kishiwada M; Usui M; Sakurai H; Isaji S
    Transplant Proc; 2018 Nov; 50(9):2699-2704. PubMed ID: 30401380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive Factors of De Novo Malignancies After Living-Donor Liver Transplantation: A Single-Center Experience.
    Wahab MA; Abdel-Khalek EE; Elshoubary M; Yassen AM; Salah T; Sultan AM; Fathy O; Elmorshedi M; Shiha U; Elsadany M; Adly R; Samy M; Shehta A
    Transplant Proc; 2021 Mar; 53(2):636-644. PubMed ID: 33549346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Outcomes and Risk Factors After Adult Living Donor Liver Transplantation.
    Imai D; Yoshizumi T; Sakata K; Ikegami T; Itoh S; Harada N; Motomura T; Toshima T; Mano Y; Soejima Y; Maehara Y
    Transplantation; 2018 Sep; 102(9):e382-e391. PubMed ID: 29912047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De Novo Malignancy After Living Donor Liver Transplantation: A Large Volume Experience.
    Tiwari A; Saigal S; Choudhary NS; Saha S; Rastogi A; Bhangui P; Saraf N; Srinivasan T; Yadav SK; Gautam D; Nundy S; Soin AS
    J Clin Exp Hepatol; 2020; 10(5):448-452. PubMed ID: 33029053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Living-donor liver transplantation at the University of Tokyo, 1996-2011: the impact of HLA matching and a positive crossmatch on long-term survival and tolerance.
    Waki K; Sugawara Y; Mizuta K; Fujita H; Kadowaki T; Kokudo N
    Clin Transpl; 2011; ():223-35. PubMed ID: 22755416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo hepatitis B virus infection from anti-HBc-positive donors in pediatric living donor liver transplantation.
    Xi ZF; Xia Q; Zhang JJ; Chen XS; Han LZ; Zhu JJ; Wang SY; Qiu DK
    J Dig Dis; 2013 Aug; 14(8):439-45. PubMed ID: 23638710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma and the risk of de novo malignancies after liver transplantation - a multicenter cohort study.
    Shalaby S; Taborelli M; Zanetto A; Ferrarese A; D'Arcangelo F; Gambato M; Senzolo M; Russo FP; Germani G; Boccagni P; Ettorre GM; Baccarani U; Lauro A; Galatioto L; Rendina M; Petrara R; De Rossi A; Nudo F; Toti L; Fantola G; Vennarecci G; Risaliti A; Pinna AD; Gruttadauria S; Di Leo A; Rossi M; Tisone G; Zamboni F; Cillo U; Piselli P; Serraino D; Burra P;
    Transpl Int; 2021 Apr; 34(4):743-753. PubMed ID: 33492715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Good outcomes of living donor liver transplant in primary sclerosing cholangitis: an experience from North India.
    Jadaun SS; Mehtani R; Hasnain A; Bhatia S; Moond V; Kumar M; Kuhad V; Singh S; Agarwal S; Gupta S; Saigal S
    Hepatol Int; 2023 Apr; 17(2):499-506. PubMed ID: 36376772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining long-term outcomes with living donor liver transplantation in North America.
    Olthoff KM; Smith AR; Abecassis M; Baker T; Emond JC; Berg CL; Beil CA; Burton JR; Fisher RA; Freise CE; Gillespie BW; Grant DR; Humar A; Kam I; Merion RM; Pomfret EA; Samstein B; Shaked A
    Ann Surg; 2015 Sep; 262(3):465-75; discussion 473-5. PubMed ID: 26258315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factors and Outcomes of De Novo Cancers (Excluding Nonmelanoma Skin Cancer) After Liver Transplantation for Primary Sclerosing Cholangitis.
    Mouchli MA; Singh S; Loftus EV; Boardman L; Talwalkar J; Rosen CB; Heimbach JK; Wiesner RH; Hasan B; Poterucha JJ; Kymberly WD
    Transplantation; 2017 Aug; 101(8):1859-1866. PubMed ID: 28272287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients.
    Gordon FD; Goldberg DS; Goodrich NP; Lok AS; Verna EC; Selzner N; Stravitz RT; Merion RM
    Liver Transpl; 2016 Sep; 22(9):1214-22. PubMed ID: 27339253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technique and outcome of domino liver transplantation from patients with maple syrup urine disease: Expanding the donor pool for live donor liver transplantation.
    Celik N; Kelly B; Soltys K; Squires JE; Vockley J; Shellmer DA; Strauss K; McKiernan P; Ganoza A; Sindhi R; Bond G; Mazariegos G; Khanna A
    Clin Transplant; 2019 Nov; 33(11):e13721. PubMed ID: 31556146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Significance of De Novo Malignancy After Liver Transplant: A Single-Center Study.
    Kim S; Rovgaliyev B; Lee JM; Lee KW; Hong SK; Cho JH; Yoon KC; Yi NJ; Suh KS
    Transplant Proc; 2021; 53(1):200-206. PubMed ID: 32409224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Living donor liver transplantation in children with cholestatic liver disease: a single-center experience.
    Mizuta K; Urahashi T; Ihara Y; Sanada Y; Wakiya T; Yamada N; Okada N; Egami S; Hishikawa S; Hyodo M; Sakuma Y; Fujiwara T; Kawarasaki H; Yasuda Y
    Transplant Proc; 2012 Mar; 44(2):469-72. PubMed ID: 22410047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for de novo hepatitis B infection in pediatric living donor liver transplantation.
    Rao W; Xie M; Yang T; Zhang JJ; Gao W; Deng YL; Zheng H; Pan C; Liu YH; Shen ZY
    World J Gastroenterol; 2014 Sep; 20(36):13159-66. PubMed ID: 25278711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo malignancies after adult-to-adult living-donor liver transplantation with a malignancy surveillance program: comparison with a Japanese population-based study.
    Kaneko J; Sugawara Y; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Yamashiki N; Kokudo N
    Transplantation; 2013 May; 95(9):1142-7. PubMed ID: 23572128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development, management, and resolution of biliary complications after living and deceased donor liver transplantation: a report from the adult-to-adult living donor liver transplantation cohort study consortium.
    Zimmerman MA; Baker T; Goodrich NP; Freise C; Hong JC; Kumer S; Abt P; Cotterell AH; Samstein B; Everhart JE; Merion RM
    Liver Transpl; 2013 Mar; 19(3):259-67. PubMed ID: 23495079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of incidentally detected hepatocellular carcinoma in explanted livers after living donor liver transplantation.
    Rajakannu M; Vij M; Shaikh TMA; Rammohan A; Reddy MS; Rela M
    Indian J Gastroenterol; 2021 Feb; 40(1):30-34. PubMed ID: 33548018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.